상세 보기
- Cherifi, Francois;
- Ray-Coquard, Isabelle;
- Rubio, Maria Jesus;
- Paoletti, Xavier;
- Lorusso, Domenica;
- ... Choi, Chel Hun;
- 외 10명
WEB OF SCIENCE
0SCOPUS
0초록
Immunotherapy (IO) in endometrial cancer (EC) is the standard of care in the second line setting in combination with an anti-angiogenic agent. Randomized clinical trials have reported results supporting the addition of IO to chemotherapy (paclitaxel plus carboplatin) in the first-line setting in advanced EC patients in the global population, with high efficacy in mismatch repair deficient (MMRd) patients. These trials were not designed to answer this de-escalation question in the MMRd population, who benefit greatly from IO. The international, randomized phase III, DOMENICA trial compares first-line dostarlimab versus chemotherapy alone (with planned cross-over) for advanced MMRd EC. Our primary endpoint will be progression-free survival. The key secondary endpoints will be overall survival, safety and quality of life [NCT05201547].
키워드
- 제목
- DOMENICA: dostarlimab versus chemotherapy alone in first-line MMR-deficient advanced endometrial cancer patients
- 저자
- Cherifi, Francois; Ray-Coquard, Isabelle; Rubio, Maria Jesus; Paoletti, Xavier; Lorusso, Domenica; Choi, Chel Hun; Hasegawa, Kosei; Tan, David Shao Peng; Hudson, Emma; Davis, Alison; Tognon, Germana; Lheureux, Stephanie; Vardar Key, Mehmet Ali; Kurtz, Jean Emmanuel; Alexandre, Jerome; Joly, Florence
- 발행일
- 2025-05
- 유형
- Article; Early Access
- 저널명
- Future Oncology
- 권
- 21
- 호
- 13
- 페이지
- 1613 ~ 1623